Saamya Biotech (India) Limited reported audited earnings results for fourth quarter and full year ended Mar. 31, 2017. For the quarter, the company reported loss from operations before other income and finance costs and exceptional items of INR 402,995,002, loss from ordinary activities before tax of INR 402,995,002, net profit of INR 402,995,002, or INR 16.2 per basic and diluted share compared to the loss from operations before other income and finance costs and exceptional items of INR 2,681,311, loss from ordinary activities before tax of INR 2,544,144, net profit of INR 2,423,518, or INR 0.1 per basic and diluted share for the same quarter a year ago. For the year, the company reported loss from operations before other income and finance costs and exceptional items of INR 411,215,833, loss from ordinary activities before tax of INR 411,223,084, net loss of INR 416,414,513, or INR 17 per basic and diluted share compared to the loss from operations before other income and finance costs and exceptional items of INR 10,472,701, loss from ordinary activities before tax of INR 9,379,210, net loss of INR 4,411,548, or INR 0.18 per basic and diluted share for the previous year.